Myelodysplastic Syndrome Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth And Forecast 2019 - 2024

Report Code: HCR 80259 Report Format: PDF + Excel (Delivery in 48 Hrs)

Overview

The global Myelodysplastic Syndrome Market size is forecast to reach $2.69 billion by 2024, growing at a CAGR of 9.68% during 2019-2024. Myelodysplastic syndrome is a condition where immature cells in the bone marrow do not mature to become healthy blood cells. Loss of a part of the long arm of chromosome 5 is a common chromosomal abnormality seen in patients with myelodysplastic syndrome. With rise in the overall geriatric population as well as with the growing awareness regarding the disease the market is set to witness noteworthy growth in coming future. Also, government initiatives such as reimbursement policies has the potential to fuel overall market growth. Commonly used treatment procedures for this disease are: stem cell transplantation and radiation therapy.


Key Takeaways

  • The North America region has been estimated to hold the largest share owing to the increased awareness as well as increased expenditure for health. Information on other major regions given in full myelodysplastic syndrome market report.
  • The rise in the overall geriatric population globally is set to drive the market. Other major growth drivers mentioned in full myelodysplastic syndrome market report.
  • The high treatment cost is considered as a challenge for the market growth. Other major challenges that has influence over the market mentioned in the full myelodysplastic syndrome market report.

Drug Class - Segment Analysis

The immunomodulatory drug class is estimated to hold the largest share in this segment. This is a drug class that is used in chemotherapy and is used for people with chromosomal abnormalities. However, the Hypomethylating drugs segment is estimated to have the largest CAGR of 8.64% during the forecast period owing to its increased use.

Geography - Segment Analysis

The North America region has been estimated to hold the dominance with myelodysplastic syndrome market share of 46.2%. This is owing to the high health expenditure cost as well as increased awareness regarding the disease and the easy availability of treatment options. However, the APAC region is estimated to have the highest CAGR during the forecast period. This is due to the rapid urbanization of Asian Countries as well as a rapid growth rate of the geriatric population. In the APAC region, Japan is set to hold the highest growth rate.

Drivers – Myelodysplastic Syndrome Market

·         Rising Geriatric Population

There is an overall increase in the geriatric population in the world. Studies has shown that the prevalence of myelodysplastic syndrome increases in elderly population and they are more likely to seek for treatment. This factor could be considered as a major market driver.

·         Government Support

The various government initiatives that provide target specific treatment as well as favorable reimbursement policies are estimated to fuel the overall myelodysplastic syndrome market. The government initiatives can also rise the overall awareness of the people.

Challenges – Myelodysplastic Syndrome Market

·         High Treatment cost

The treatment for myelodysplastic syndrome requires huge capital input. Also, other risks associated with the treatment are present which can make the people reluctant to obtain the treatment. This factor has the potential to limit the overall market growth.

Myelodysplastic Syndrome Industry Outlook

Partnerships and Product Launches are the key strategies employed by the major players of this market. Myelodysplastic Syndrome top 10 companies include: Celgene Corporation, Cipla, Inc., Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Johnson & Johnson, Lupin Ltd., Otsuka Pharmaceutical Co., Ltd., Pfizer, Inc., Amgen Inc. and Takeda Pharmaceutical Company Limited., among others.

Partnerships/Product Launches

  • On January 2015, Amgen and MD Anderson Cancer Center had announced an agreement for developing BiTE therapies for Myelodysplastic syndrome. This collaboration will call on the use of the MD Anderson Cancer Centre’s Moon Shots Program that aims to convert scientific discoveries into clinical advances at a much faster rate.
  • On March 2017, Janssen-Cilag International N.V.(Johnson & Johnson) had announced that the product named “EPREX”for the treatment of symptomatic anemia for myelodysplastic syndrome has been approved for marketing by the French Authority Agence Nationale de Sécurité du Médicament et des Produits de Santé

1. Myelodysplastic Syndrome Market - Overview
        1.1 Definitions and Scope
2. Myelodysplastic Syndrome Market - Executive summary
        2.1 Market Revenue, Market Size and Key Trends by Company
        2.2 Key Trends by type of Application
        2.3 Key Trends segmented by Geography
3. Myelodysplastic Syndrome Market
        3.1 Comparative analysis
            3.1.1 Product Benchmarking - Top 10 companies
            3.1.2 Top 5 Financials Analysis
            3.1.3 Market Value split by Top 10 companies
            3.1.4 Patent Analysis - Top 10 companies
            3.1.5 Pricing Analysis
4. Myelodysplastic Syndrome Market - Startup companies Scenario Premium
        4.1 Top 10 startup company Analysis by
            4.1.1 Investment
            4.1.2 Revenue
            4.1.3 Market Shares
            4.1.4 Market Size and Application Analysis
            4.1.5 Venture Capital and Funding Scenario
5. Myelodysplastic Syndrome Market - Industry Market Entry Scenario Premium
        5.1 Regulatory Framework Overview
        5.2 New Business and Ease of Doing business index
        5.3 Case studies of successful ventures
        5.4 Customer Analysis - Top 10 companies
6. Myelodysplastic Syndrome Market Forces
        6.1 Drivers
        6.2 Constraints
        6.3 Challenges
        6.4 Porters five force model
            6.4.1 Bargaining power of suppliers
            6.4.2 Bargaining powers of customers
            6.4.3 Threat of new entrants
            6.4.4 Rivalry among existing players
            6.4.5 Threat of substitutes
7. Myelodysplastic Syndrome Market -Strategic analysis
        7.1 Value chain analysis
        7.2 Opportunities analysis
        7.3 Product life cycle
        7.4 Suppliers and distributors Market Share
8. Myelodysplastic Syndrome Market - By Product (Market Size -$Million / $Billion)
        8.1 Market Size and Market Share Analysis
        8.2 Application Revenue and Trend Research
        8.3 Product Segment Analysis
9. Myelodysplastic Syndrome Market - By Drug (Market Size -$Million / $Billion)
9.1 Azacitidine
9.2 Lenalidomide
9.3 Decitabine
9.4 Deferasirox
10. Myelodysplastic Syndrome - By Application (Market Size -$Million / $Billion)
        10.1 Segment type Size and Market Share Analysis
        10.2 Application Revenue and Trends by type of Application
        10.3 Application Segment Analysis by Type
11. Myelodysplastic Syndrome- By Geography (Market Size -$Million / $Billion)
        11.1 Myelodysplastic Syndrome Market - North America Segment Research
        11.2 North America Market Research (Million / $Billion)
            11.2.1 Segment type Size and Market Size Analysis
            11.2.2 Revenue and Trends
            11.2.3 Application Revenue and Trends by type of Application
            11.2.4 Company Revenue and Product Analysis
            11.2.5 North America Product type and Application Market Size
                  11.2.5.1 U.S
                  11.2.5.2 Canada
                  11.2.5.3 Mexico
                  11.2.5.4 Rest of North America
        11.3 Myelodysplastic Syndrome- South America Segment Research
        11.4 South America Market Research (Market Size -$Million / $Billion)
            11.4.1 Segment type Size and Market Size Analysis
            11.4.2 Revenue and Trends
            11.4.3 Application Revenue and Trends by type of Application
            11.4.4 Company Revenue and Product Analysis
            11.4.5 South America Product type and Application Market Size
                  11.4.5.1 Brazil
                  11.4.5.2 Venezuela
                  11.4.5.3 Argentina
                  11.4.5.4 Ecuador
                  11.4.5.5 Peru
                  11.4.5.6 Colombia
                  11.4.5.7 Costa Rica
                  11.4.5.8 Rest of South America
        11.5 Myelodysplastic Syndrome- Europe Segment Research
        11.6 Europe Market Research (Market Size -$Million / $Billion)
            11.6.1 Segment type Size and Market Size Analysis
            11.6.2 Revenue and Trends
            11.6.3 Application Revenue and Trends by type of Application
            11.6.4 Company Revenue and Product Analysis
            11.6.5 Europe Segment Product type and Application Market Size
                  11.6.5.1 U.K
                  11.6.5.2 Germany
                  11.6.5.3 Italy
                  11.6.5.4 France
                  11.6.5.5 Netherlands
                  11.6.5.6 Belgium
                  11.6.5.7 Denmark
                  11.6.5.8 Spain
                  11.6.5.9 Rest of Europe
        11.7 Myelodysplastic Syndrome - APAC Segment Research
        11.8 APAC Market Research (Market Size -$Million / $Billion)
            11.8.1 Segment type Size and Market Size Analysis
            11.8.2 Revenue and Trends
            11.8.3 Application Revenue and Trends by type of Application
            11.8.4 Company Revenue and Product Analysis
            11.8.5 APAC Segment - Product type and Application Market Size
                  11.8.5.1 China
                  11.8.5.2 Australia
                  11.8.5.3 Japan
                  11.8.5.4 South Korea
                  11.8.5.5 India
                  11.8.5.6 Taiwan
                  11.8.5.7 Malaysia
                  11.8.5.8 Hong kong
                  11.8.5.9 Rest of APAC
        11.9 Myelodysplastic Syndrome - Middle East Segment and Africa Segment Research
        11.10 Middle East & Africa Market Research (Market Size -$Million / $Billion)
            11.10.1 Segment type Size and Market Size Analysis
            11.10.2 Revenue and Trend Analysis
            11.10.3 Application Revenue and Trends by type of Application
            11.10.4 Company Revenue and Product Analysis
            11.10.5 Middle East Segment Product type and Application Market Size
                  11.10.5.1 Israel
                  11.10.5.2 Saudi Arabia
                  11.10.5.3 UAE
            11.10.6 Africa Segment Analysis
                  11.10.6.1 South Africa
                  11.10.6.2 Rest of Middle East & Africa
12. Myelodysplastic Syndrome Market - Entropy
        12.1 New product launches
        12.2 M&A s, collaborations, JVs and partnerships
13. Myelodysplastic Syndrome Market - Industry / Segment Competition landscape Premium
        13.1 Market Share Analysis
            13.1.1 Market Share by Country- Top companies
            13.1.2 Market Share by Region- Top 10 companies
            13.1.3 Market Share by type of Application - Top 10 companies
            13.1.4 Market Share by type of Product / Product category- Top 10 companies
            13.1.5 Market Share at global level - Top 10 companies
            13.1.6 Best Practises for companies
14. Myelodysplastic Syndrome Market - Key Company List by Country Premium
15. Myelodysplastic Syndrome Market Company Analysis
15.1 Market Share, Company Revenue, Products, M&A, Developments
15.2 Amgen
15.3 Celgene
15.4 Otsuka
15.5 Takeda
15.6 Company 5
15.7 Company 6 & More
*Financials would be provided on a best efforts basis for private companies
16. Myelodysplastic Syndrome Market - Appendix
        16.1 Abbreviations
        16.2 Sources
17. Myelodysplastic Syndrome Market - Methodology
        17.1 Research Methodology
            17.1.1 Company Expert Interviews
            17.1.2 Industry Databases
            17.1.3 Associations
            17.1.4 Company News
            17.1.5 Company Annual Reports
            17.1.6 Application Trends
            17.1.7 New Products and Product database
            17.1.8 Company Transcripts
            17.1.9 R&D Trends
            17.1.10 Key Opinion Leaders Interviews
            17.1.11 Supply and Demand Trends

List of Tables

1 US Myelodysplastic Syndrome Market Size 2018
2 Canada Myelodysplastic Syndrome Market Share 2018
3 Brazil Myelodysplastic Syndrome Market Outlook 2019 - 2023
4 Mexico Myelodysplastic Syndrome Market Research 2018
5 Germany Myelodysplastic Syndrome Market Trends 2019 - 2023 
6 France Myelodysplastic Syndrome Market Growth 2019 - 2023 
7 UK Myelodysplastic Syndrome Market Demand 2019 - 2023 
8 Italy Myelodysplastic Syndrome Market Segmentation 2018
9 Russia Myelodysplastic Syndrome Market Analysis 2019 - 2023
10 China Myelodysplastic Syndrome Market Revenue 2019 - 2023
11 Japan Myelodysplastic Syndrome Market Volume 2019 - 2023
12 South Korea Myelodysplastic Syndrome Market Potential 2019 - 2023
13 India Myelodysplastic Syndrome Market Leaders 2018
14 Saudi Arabia Myelodysplastic Syndrome Market Forecast 2019 - 2023 
15 Kuwait Myelodysplastic Syndrome Market Value 2018

List of Figures

For complete list of 60+ tables and 60+ figures follow the Link